Skip to content
Botulinum Toxin Index

People

People coverage tracks publicly documented executives, scientists, founders, and other industry figures whose roles help explain the botulinum toxin market. The first entries start with Allergan Aesthetics because the organization connects Botox Cosmetic, AbbVie ownership, aesthetic R&D, and later leadership movement into other medical-aesthetics companies.

Directory

Section titled “Directory”
NameCurrent organization / rolePublic / social links
Nicole Mowad-NassarAbbVie; Senior Vice President, AbbVie and President, Global Allergan AestheticsAbbVie bio; LinkedIn
Darin J. Messina, Ph.D.AbbVie / Allergan Aesthetics; Senior Vice President, Aesthetics R&DAllergan Aesthetics science page; LinkedIn
Carrie StromHugel; President and Global Chief Executive Officer; former Global President of Allergan AestheticsHugel announcement; LinkedIn

Reading Paths

Section titled “Reading Paths”
QuestionUseful path
Which leaders explain AbbVie’s aesthetic-toxin business?Start with Nicole Mowad-Nassar for the current Global Allergan Aesthetics commercial role and Darin J. Messina, Ph.D. for aesthetics R&D.
How did Allergan Aesthetics become a distinct AbbVie business node?AbbVie / Allergan gives the company context, while Carrie Strom anchors the 2020 launch leadership.
Why does leadership movement matter for the toxin market graph?The movement from Allergan Aesthetics to Hugel links established Botox Cosmetic commercial experience with Letybo’s global expansion context.